Luigi Aurisicchio
Chief Executive Officer and Chief Scientific Officer
CHR HANSEN
Italy
Biography
Luigi Aurisicchio, PhD, received his Laurea in Biology in 1996 at the University of Napoli "Federico II". At the Stazione Zoologica A. Dohrn in Napoli characterized signal transduction mechanisms in thyroid cancer. In 1997, joined IRBM/MRL focusing on the development of gene therapy approaches for the cure of viral hepatitis. Subsequently contributed to the approval and development of Cancer Vaccine program, being Research Group Leader in the last 5 years. His research interests include the discovery, characterization and engineering of novel tumor associated antigens for cancer vaccines, but also intratumoral delivery of siRNAs, generation of novel monoclonal antibodies and development of Oncology pre-clinical models. Has published >60 papers in peer reviewed International Journals and is author of 8 patents.
Research Interest
His research interests include the discovery, characterization and engineering of novel tumor associated antigens for cancer vaccines, but also intratumoral delivery of siRNAs, generation of novel monoclonal antibodies and development of Oncology pre-clinical models.
